Study partner‐reported decline identifies cognitive decline and dementia risk
Abstract
Identifying individuals at risk for cognitive decline, Mild Cognitive Impairment (MCI), and dementia due to Alzheimer’s disease (AD) is a critical need. Functional decline is associated with risk and can be efficiently assessed by participants and study partners (SPs). We tested the hypothesis that SP‐reported functional decline is an independent predictor of dementia risk and cognitive decline.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 13, 2019
- Source ID
- 10.1002/acn3.50938
Entities
People
- Alzheimer’s Disease Neuroimaging Initiative Investigators
- Chengshi Jin
- John Neuhaus
- Michael W. Weiner
- Philip S Insel
- Rachel L Nosheny
- Robert Scott Mackin
Organizations
- AbbVie
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Innogenetics
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of California, San Francisco